Cisplatin News and Research

RSS

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."

2 Jun 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.

21 May 2015

Scientists identify new molecules that destroy cancer cells, save healthy ones

Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.

15 May 2015

Discovery could help identify molecules that selectively target cancer cells

A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.

13 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

It’s been nine years since Harry Folk of Palmer Township had a scare with throat cancer. He is able to talk about his journey, literally, thanks to the treatment he received at St. Luke’s. The treatment plan recommended by his cancer team not only removed his cancer, but preserved his voice and ability to swallow without difficulty.

8 Apr 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers at The Ohio State University Wexner Medical Center have shown that a protein known as MG53 is not only present in kidney cells, but necessary for the organ to repair itself after acute injury. Results from this animal model study are published in the journal Science Translational Medicine.

19 Mar 2015

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Chemists at Bielefeld University have developed a molecule containing copper that binds specifically with DNA and prevents the spread of cancer. First results show that it kills the cancer cells more quickly than cisplatin - a widely used anti-cancer drug that is frequently administered in chemotherapy.

2 Mar 2015

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Boosting anti-cancer immunity through diet and novel drug therapies—that's the idea behind a collaborative project involving researchers from the South Dakota State University College of Pharmacy and Sanford Research in Sioux Falls.

27 Feb 2015

Researchers discover inherited genetic variations associated with treatment-related hearing loss

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.

10 Feb 2015

Cisplatin News and Research

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Scientists identify new molecules that destroy cancer cells, save healthy ones

Discovery could help identify molecules that selectively target cancer cells

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Researchers discover inherited genetic variations associated with treatment-related hearing loss

SRS fails to improve survival for NSCLC brain metastases patients

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

MD Anderson study sheds light on miR569 gene

Faster and more accurate method for testing new cancer drugs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News